Auditory outcomes show durable improvement: ABR thresholds drop from roughly 97 dB at baseline to about 42 dB after 2.5 years, with behavioral audiometry confirming meaningful gains across participants.

Overall, the study demonstrates sustained hearing restoration with gene therapy for OTOF-related deafness, challenging the notion that this condition is irreversible and pointing toward broader clinical adoption.

The treatment is described as potentially one-and-done, offering lifelong benefits in many cases, though longer follow-up is needed to confirm long-term safety and efficacy.

Early diagnosis and genetic screening, along with biomarkers, may help optimize patient selection and outcomes in future applications.

No dose-limiting toxicities were observed within six weeks post-injection; adverse events were generally mild, with only a few Grade 3 events like decreased neutrophil counts that were clinically manageable.

The report is an exclusive STAT+ piece with author background on disability health policy and technologies, indicating comprehensive, industry-focused coverage.

Results were published in Nature and described as among the most promising to date by the study authors.

Regeneron’s work could represent the first FDA-approved gene therapy for deafness, with U.S. trials likely required; the Chinese trial will continue through its regulatory process.

Adults benefited less than children and teens, but several adults still showed meaningful improvements; no serious adverse effects were observed beyond mild immune fluctuations and rare inner ear inflammation.

Next steps include exploring multiple dosing and longer follow-up to assess durability, while comparing with cochlear implants—benefits in music and noisy environments may exist, but implants may remain the default for many patients.

The study drew on multi-institutional collaboration across eight centers, providing robust longitudinal data over 2.5 years supporting safety and efficacy across a broad age range.

The trial used AAV1 vectors targeting cochlear hair cells with a codon-optimized human OTOF transgene, illustrating precise molecular engineering for a sensory disorder.